US Patent

US12251468 — Manufacturing of bupivacaine multivesicular liposomes

Method of Use · Assigned to Pacira Pharmaceuticals Inc · Expires 2044-07-02 · 18y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects a new manufacturing process for making bupivacaine multivesicular liposomes with high yields, improved stabilities, and desired particle size distributions.

USPTO Abstract

Embodiments of the present disclosure relates to a new and improved large scale commercial manufacturing process of making bupivacaine multivesicular liposomes (MVLs). Batches of bupivacaine MVLs prepared by the new process have high yields, improved stabilities, and desired particle size distributions.

Drugs covered by this patent

Bupivacaine Hydrochloride And Epinephrine (BUPIVACAINE) · Innocoll

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-4152`	—	Bupivacaine Hydrochloride And Epinephrine
`U-4152`	—	Bupivacaine Hydrochloride And Epinephrine

Patent Metadata

Patent number: US12251468
Jurisdiction: US
Classification: Method of Use
Expires: 2044-07-02
Drug substance claim: No
Drug product claim: Yes
Assignee: Pacira Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.